Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04844866
Title Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (DALY 2-EU)
Acronym DALY 2-EU
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Miltenyi Biomedicine GmbH
Age Groups: adult | senior
Covered Countries NLD | ITA | FRA | ESP | DEU | BEL | AUT

No variant requirements are available.